Clinical Trials | March 14, 2026
Gesynta Pharma launches Phase 2 trial of promising Endometriosis drug
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
The new facilities are designed to provide focused, patient-centric care through advanced diagnostics, minimally invasive treatments, and multidisciplinary expertise
Diasens and GlucoLive are designed for diabetic, Chronic Kidney Disease (CKD), and post-transplant patients who require continuous glycaemic surveillance and integrated remote care
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
Germany will be the first launch market
The first of four planned modules at the new plant is expected to come online by summer 2026
The company says those insights can power advanced analytics and real-world evidence (RWE), helping researchers improve trial design, study feasibility, and recruitment strategies
ShunzymeX leverages a proprietary protease to streamline purification
Subscribe To Our Newsletter & Stay Updated
